title: Recovery of hematopoietic activity in bone marrow from human immunodeficiency virus type 1-infected patients during highly active antiretroviral therapy.
abstract: The mechanisms responsible for the hematopoietic failure in human immunodeficiency virus type 1 (HIV-1)-infected patients are still unknown. Several findings indicate that the in vitro proliferative potential of precursor cells from AIDS patients is reduced. The changes seen in bone marrow (BM) morphology and the defective BM functions associated with cytopenias have both been proposed as potential explanations. In patients treated with highly active antiretroviral therapy (HAART) an immune reconstitution associated with increased whole blood cell counts has been described. We have investigated the effects of HAART on the number of colony-forming cells (CFCs) and long-term culture-initiating cells (LTC-ICs), using long-term BM cell cultures (LTBMC) in a group of subjects with HIV-1 infection enrolled in an open study to evaluate the mechanisms of immune reconstitution during HAART. In each patient, the increase in colony growth was homogeneous, regardless of the type of hematopoietic progenitor cells assayed; in four subjects an increase in the most primitive progenitor cells (LTC-ICs) was observed. These findings were associated with the in vivo data showing increased numbers of BM mononuclear cells (BMMCs) after HAART and with a rise in peripheral CD4(+) T cell counts and decreased levels of plasma HIV-1 RNA. A decreased number of hematopoietic progenitor cells and/or a defective modulation of progenitor cell growth might be the cause of the hematological abnormalities in AIDS patients. Controlling HIV-1 replication by HAART could determine a restoration of stem cell activity, probably because of the suppression of factors that inhibit normal hematopoiesis.
authors.affiliation: Division of Allergy and Clinical Immunology, University of Rome La Sapienza, 00185 Rome, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Isgrò
authors.forename: I
authors.initials: I
authors.lastname: Mezzaroma
authors.forename: A
authors.initials: A
authors.lastname: Aiuti
authors.forename: L
authors.initials: L
authors.lastname: De Vita
authors.forename: F
authors.initials: F
authors.lastname: Franchi
authors.forename: F
authors.initials: F
authors.lastname: Pandolfi
authors.forename: C
authors.initials: C
authors.lastname: Alario
authors.forename: F
authors.initials: F
authors.lastname: Ficara
authors.forename: E
authors.initials: E
authors.lastname: Riva
authors.forename: G
authors.initials: G
authors.lastname: Antonelli
authors.forename: F
authors.initials: F
authors.lastname: Aiuti
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001853:Bone Marrow / Q000276:immunology; D002478:Cells, Cultured; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D005434:Flow Cytometry; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D006405:Hematology; D006410:Hematopoiesis / Q000276:immunology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D008297:Male; D008747:Methylcellulose; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D013997:Time Factors
chemical_list: D004279:DNA, Viral; D008747:Methylcellulose